Payment overview · 2025
General Payments
$257.00
14 reported records · 9 companies
Healthcare provider profile · identity verified
Luc Tchapnda, MD
Allopathic & Osteopathic Physicians|Family Medicine · QUINCY, IL · NPI 1801044763
Verified facts
What the public records show
CMS Open Payments records show Luc Tchapnda, MD received $257.00 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.16 | 22.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.86 | 19.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.51 | 13.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.27 | 9.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.61 | 8.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.23 | 7.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.48 | 7.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.47 | 6.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.41 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $257.00 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.84 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 518 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 73 |
| Lisinopril | Lisinopril | 312 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 291 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 63 |
| Metformin Hcl | Metformin Hcl | 244 | 64 |
| Gabapentin | Gabapentin | 195 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 43 |
| Furosemide | Furosemide | 177 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 163 | 50 |
| Losartan Potassium | Losartan Potassium | 140 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 38 |
| Sertraline Hcl | Sertraline Hcl | 129 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 28 |
| Simvastatin | Simvastatin | 112 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 26 |
| Glipizide Er | Glipizide | 105 | 21 |
| Jardiance | Empagliflozin | 105 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 18 |
| Carvedilol | Carvedilol | 93 | 23 |
| Potassium Chloride | Potassium Chloride | 93 | 30 |
| Eliquis | Apixaban | 88 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 18 |
| Omeprazole | Omeprazole | 85 | 25 |
| Fenofibrate | Fenofibrate,micronized | 83 | 16 |
| Allopurinol | Allopurinol | 82 | 20 |
| Famotidine | Famotidine | 81 | 22 |
| Ozempic | Semaglutide | 78 | 19 |
| Montelukast Sodium | Montelukast Sodium | 74 | 22 |
| Celecoxib | Celecoxib | 71 | 11 |
| Ezetimibe | Ezetimibe | 67 | 19 |
| Glipizide | Glipizide | 65 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 23 |
| Donepezil Hcl | Donepezil Hcl | 62 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 54 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 16 |
| Metformin Hcl Er | Metformin Hcl | 53 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | 18 |
| Gemfibrozil | Gemfibrozil | 51 | 14 |
| Propranolol Hcl | Propranolol Hcl | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 16 |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Prednisone | Prednisone | 48 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 16 |
| Chlorthalidone | Chlorthalidone | 46 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 37 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Spironolactone | Spironolactone | 43 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 12 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 29 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | 15 |
| Baclofen | Baclofen | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 15 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | 11 |
| Colchicine | Colchicine | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | 11 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $257.00 · 14 records | Novo Nordisk Inc | CAPLYTA, Cologuard Collection Kit, ENTRESTO, EVENITY, FREESTYLE LIBRE 3, LEQVIO, OTEZLA, Ozempic, PENMENVY, REPATHA, Rybelsus, SHINGRIX, VOQUEZNA, WATCHMAN Access System, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error